15 April 2026 : Clinical Research
Phospho-Histone H3 as a Tool for Improved Mitotic Counting and Risk Assessment in Gastrointestinal Stromal Tumors: A Study of 241 Cases
Xu LiuDOI: 10.12659/MSM.952182
Med Sci Monit 2026; 32:e952182
Table 3 Comparison of RS based on MC-HE and MC-PHH3.
| Case | Sex/age | Tumor site | MC-HE (5 mm2/21HPF) | RS | MC-PHH3 (5 mm2/21HPF) | RS |
|---|---|---|---|---|---|---|
| 1 | Male/64y | Stomach | 4 | Low | 8 | Medium |
| 2 | Female/58y | Stomach | 2 | Low | 6 | Medium |
| 3 | Male/53y | Stomach | 9 | Medium | 12 | High |
| 4 | Male/53y | Stomach | 9 | Medium | 15 | High |
| 5 | Female/42y | Small intestine | 3 | Very low | 6 | Medium |
| 6 | Male/53y | Small intestine | 6 | Medium | 11 | High |
| 7 | Female/62y | Small intestine | 8 | Medium | 14 | High |
| 8 | Female/48y | Large intestine | 7 | Medium | 12 | High |
| 9 | Female/63y | Stomach | 12 | High | 8 | Medium |
| 10 | Male/61y | Stomach | 11 | High | 9 | Medium |
| 11 | Male/50y | Stomach | 7 | Medium | 4 | Low |
| 12 | Female/45y | Small intestine | 10 | High | 4 | Low |
| RS – risk stratification; MC-HE – mitotic count on hematoxylin-eosin; MC-PHH3 – mitotic count on phospho-histone H3; HPF – high-power field. | ||||||






